STA
KDNY

Summit Trail Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Summit Trail Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-7
Closed – – 1794
2017
Q4 		$0 Buy
+7
New +$306 ﹤0.01% 2120

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Trail Advisors's KDNY Position: Q1 2018 in Review

Summit Trail Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2018, closing a stake of 7 shares.

Summit Trail Advisors first reported a position in KDNY in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 92 funds tracked by Wall St. Rank hold KDNY as of Q1 2018.

  • Summit Trail Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 7 Chinook Therapeutics, Inc. Common Stock shares in Q1 2018.
  • Summit Trail Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $0 in Q4 2017.
  • 92 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.